LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors.
Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased ACADIA securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
